First O O O O
discovered O O O O
in O O O O
1961 O O O O
and O O O O
leading O O O O
up O O O O
to O O O O
the O O O O
70s, O O O O
amiodarone O O O O
was O O O O
used O O O O
for O O O O
its O O O O
antiarrhythmic O O O O
properties, O O O O
although O O O O
not O O O O
officially O O O O
before O O O O
the O O O O
year O O O O
1985, O O O O
when O O O O
the O O O O
United O O O O
States O O O O
finally O O O O
approved O O O O
its O O O O
use. O O O O
The O O O O
Food O O O O
and O O O O
Drug O O O O
Administration O O O O
(FDA) O O O O
had O O O O
been O O O O
reluctant O O O O
to O O O O
approve O O O O
the O O O O
drug O O O O
due Reason 2 O O
to Reason 2 O O
initial Reason 2 O O
reports Reason 2 O O
showing Reason 2 O O
an Reason 2 O O
increased Reason 2 O O
incidence Reason 2 O O
of Reason 2 O O
adverse Reason 2 O O
pulmonary Reason 2 O O
effects. Reason 2 O O
European O O O O
pharmaceutical O O O O
companies O O O O
began O O O O
discussing O O O O
with O O O O
the O O O O
institution O O O O
in O O O O
the O O O O
mid-80s O O O O
and O O O O
threatened O O O O
to O O O O
suspend O O O O
their O O O O
(free) O O O O
supply O O O O
of O O O O
the O O O O
drug O O O O
to O O O O
American O O O O
physicians, O O O O
should O O O O
the O O O O
FDA O O O O
not O O O O
grant O O O O
official O O O O
approval. O O O O
Authorisation O O O O
was O O O O
finally O O O O
issued O O O O
in O O O O
December O O O O
1985, O O O O
making O O O O
it O O O O
one O O O O
of O O O O
the O O O O
few O O O O
drugs O O O O
approved O O O O
by O O O O
the O O O O
FDA O O O O
without O O O O
prior O O O O
randomised O O O O
clinical O O O O
trials. O O O O
I O O O O
- O O O O
Mechanism O O O O
of O O O O
action O O O O
and O O O O
pharmacologist O O O O
effects O O O O
The O O O O
two O O O O
atoms O O O O
of O O O O
iodine O O O O
contained O O O O
in O O O O
the O O O O
amiodarone O O O O
molecule, O O O O
a O O O O
benzofuran O O O O
derivative, O O O O
are O O O O
essential O O O O
to O O O O
its O O O O
antiarrhythmic O O O O
properties. O O O O
Using Reason 4 O O
the Reason 4 O O
Vaughan-Williams Reason 4 O O
classification Reason 4 O O
of Reason 4 O O
antiarrhythmic Reason 4 O O
drugs, Reason 4 O O
amiodarone Reason 4 O O
prolongs Reason 4 O O
the Reason 4 O O
Phase Reason 4 O O
3 Reason 4 O O
action Reason 4 O O
potential Reason 4 O O
of Reason 4 O O
cardiac Reason 4 O O
cells Reason 4 O O
and Reason 4 O O
it Reason 4 O O
also Reason 4 O O
has Reason 4 O O
all Reason 4 O O
the Reason 4 O O
Class Reason 4 O O
4 Reason 4 O O
electrophysiological Reason 4 O O
characteristics Reason 4 O O
as Reason 4 O O
well. Reason 4 O O
Absorption O O O O
is O O O O
extremely O O O O
slow, O O O O
and O O O O
bioavailability O O O O
is O O O O
also O O O O
low O O O O
and O O O O
variable. O O O O
Low-dose Reason 3 O O
amiodarone Reason 3 O O
(100-300 Reason 3 O O
mg Reason 3 O O
per Reason 3 O O
day) Reason 3 O O
is Reason 3 O O
effective Reason 3 O O
for Reason 3 O O
a Reason 3 O O
wide Reason 3 O O
variety Reason 3 O O
of Reason 3 O O
ventricular Reason 3 O O
and Reason 3 O O
supraventricular Reason 3 O O
arrhythmias, Reason 3 O O
including Reason 3 O O
as Reason 3 O O
part Reason 3 O O
of Reason 3 O O
a Reason 3 O O
rhythm Reason 3 O O
control Reason 3 O O
strategy Reason 3 O O
for Reason 3 O O
patients Reason 3 O O
with Reason 3 O O
atrial Reason 3 O O
fibrillation, Reason 3 O O
especially Reason 3 O O
when Reason 3 O O
structural Reason 3 O O
heart Reason 3 O O
disease Reason 3 O O
is Reason 3 O O
present. Reason 3 O O
Where O O O O
other O O O O
drugs O O O O
have O O O O
failed O O O O
to O O O O
control O O O O
arrhythmias, O O O O
high Reason 2 O O
doses Reason 2 O O
of Reason 2 O O
amiodarone Reason 2 O O
will Reason 2 O O
be Reason 2 O O
required Reason 2 O O
and Reason 2 O O
produce Reason 2 O O
an Reason 2 O O
increase Reason 2 O O
in Reason 2 O O
the Reason 2 O O
incidence Reason 2 O O
of Reason 2 O O
serious Reason 2 O O
adverse Reason 2 O O
side Reason 2 O O
effects. Reason 2 O O
II O O O O
- O O O O
Impact O O O O
of O O O O
amiodarone O O O O
therapy O O O O
on O O O O
survival O O O O
in O O O O
the O O O O
clinical O O O O
setting O O O O
Several Reason 1 O O
side Reason 1 O O
effects Reason 1 O O
have Reason 1 O O
been Reason 1 O O
described Reason 1 O O
over Reason 1 O O
time, Reason 1 O O
especially Reason 1 O O
in Reason 1 O O
cases Reason 1 O O
of Reason 1 O O
chronic Reason 1 O O
use. Reason 1 O O
It Reason 1 O O
is Reason 1 O O
estimated Reason 1 O O
that Reason 1 O O
the Reason 1 O O
prevalence Reason 1 O O
of Reason 1 O O
adverse Reason 1 O O
effects Reason 1 O O
related Reason 1 O O
to Reason 1 O O
treatment Reason 1 O O
with Reason 1 O O
amiodarone Reason 1 O O
is Reason 1 O O
15% Reason 1 O O
the Reason 1 O O
first Reason 1 O O
year Reason 1 O O
and Reason 1 O O
50% Reason 1 O O
in Reason 1 O O
cases Reason 1 O O
of Reason 1 O O
prolonged Reason 1 O O
administration. Reason 1 O O
In Reason 1 O O
addition, Reason 1 O O
20% Reason 1 O O
of Reason 1 O O
patients Reason 1 O O
require Reason 1 O O
discontinued Reason 1 O O
therapy Reason 1 O O
due Reason 1 O O
to Reason 1 O O
effects Reason 1 O O
such Reason 1 O O
as Reason 1 O O
liver Reason 1 O O
damage, Reason 1 O O
problems Reason 1 O O
with Reason 1 O O
thyroid Reason 1 O O
function Reason 1 O O
and Reason 1 O O
chronic Reason 1 O O
pulmonary Reason 1 O O
sequel, Reason 1 O O
which Reason 1 O O
have Reason 1 O O
been Reason 1 O O
described Reason 1 O O
in Reason 1 O O
up Reason 1 O O
to Reason 1 O O
1% Reason 1 O O
per Reason 1 O O
year Reason 1 O O
of Reason 1 O O
treatment, Reason 1 O O
with Reason 1 O O
cumulative Reason 1 O O
damage Reason 1 O O
of Reason 1 O O
between Reason 1 O O
5% Reason 1 O O
and Reason 1 O O
10%. Reason 1 O O
Lung O O O O
damage O O O O
is O O O O
the O O O O
best O O O O
known: O O O O
it O O O O
is O O O O
produced O O O O
after O O O O
long O O O O
exposure O O O O
to O O O O
amiodarone O O O O
(2.3), O O O O
but O O O O
there O O O O
also O O O O
have O O O O
been O O O O
reports O O O O
of O O O O
acute O O O O
toxicity. O O O O
Clinical Reason 1 O O
evidence Reason 1 O O
of Reason 1 O O
hypothyroidism Reason 1 O O
occurs Reason 1 O O
in Reason 1 O O
up Reason 1 O O
to Reason 1 O O
20% Reason 1 O O
of Reason 1 O O
patients Reason 1 O O
taking Reason 1 O O
amiodarone. Reason 1 O O
Amiodarone O O O O
prevents O O O O
peripheral O O O O
conversion O O O O
of O O O O
T4 O O O O
to O O O O
T3 O O O O
and O O O O
alters O O O O
thyroid O O O O
function O O O O
tests. O O O O
The O O O O
large O O O O
amounts O O O O
of O O O O
iodine O O O O
contained O O O O
in O O O O
amiodarone O O O O
may O O O O
explain O O O O
these O O O O
effects. O O O O
Hypothyroidism O O O O
is O O O O
easily O O O O
managed O O O O
with O O O O
levothyroxine O O O O
and O O O O
is O O O O
generally O O O O
not O O O O
a O O O O
cause O O O O
for O O O O
discontinuing O O O O
amiodarone. O O O O
Hyperthyroidism Reason 2 O O
occurs Reason 2 O O
in Reason 2 O O
3% Reason 2 O O
of Reason 2 O O
patients Reason 2 O O
in Reason 2 O O
iodine-deficient Reason 2 O O
areas, Reason 2 O O
but Reason 2 O O
in Reason 2 O O
20% Reason 2 O O
in Reason 2 O O
areas Reason 2 O O
in Reason 2 O O
areas Reason 2 O O
where Reason 2 O O
iodine Reason 2 O O
is Reason 2 O O
sufficient. Reason 2 O O
It O O O O
can O O O O
be O O O O
difficult O O O O
to O O O O
recognise O O O O
because O O O O
many O O O O
of O O O O
the O O O O
typical O O O O
adrenergically O O O O
mediated O O O O
signs O O O O
are O O O O
blocked O O O O
by O O O O
amiodarone. O O O O
In O O O O
all O O O O
patients, O O O O
thyrotropin O O O O
levels O O O O
should O O O O
be O O O O
checked O O O O
before O O O O
initiating O O O O
amiodarone O O O O
therapy O O O O
and O O O O
every O O O O
every O O O O
months O O O O
thereafter. O O O O
Other Reason 1 O O
reported Reason 1 O O
side Reason 1 O O
effects Reason 1 O O
include Reason 1 O O
photosensitivity Reason 1 O O
and Reason 1 O O
blue Reason 1 O O
skin Reason 1 O O
pigmentation, Reason 1 O O
which Reason 1 O O
disappear Reason 1 O O
after Reason 1 O O
discontinuation Reason 1 O O
of Reason 1 O O
treatment. Reason 1 O O
In O O O O
our O O O O
patient, O O O O
after O O O O
completing O O O O
various O O O O
tests O O O O
and O O O O
suspecting O O O O
that O O O O
the O O O O
patient's O O O O
clinical O O O O
picture O O O O
corresponded O O O O
to O O O O
TPA, O O O O
amiodarone O O O O
was O O O O
discontinued O O O O
and O O O O
corticosteroid O O O O
therapy O O O O
was O O O O
initiated O O O O
(40-60 O O O O
mg O O O O
daily O O O O
dose O O O O
for O O O O
six O O O O
months O O O O
down). O O O O
With O O O O
this O O O O
treatment, O O O O
the O O O O
patient O O O O
experienced O O O O
satisfactory O O O O
clinical O O O O
and O O O O
radiological O O O O
recovery. O O O O
Finally, Reason 2 O O
amiodarone Reason 2 O O
may Reason 2 O O
cause Reason 2 O O
hypotension Reason 2 O O
in Reason 2 O O
approximately Reason 2 O O
15% Reason 2 O O
of Reason 2 O O
patients Reason 2 O O
receiving Reason 2 O O
it Reason 2 O O
intravenously. Reason 2 O O
Hypotension Reason 2 O O
can Reason 2 O O
be Reason 2 O O
treated Reason 2 O O
initially Reason 2 O O
by Reason 2 O O
decreasing Reason 2 O O
the Reason 2 O O
infusion Reason 2 O O
rate. Reason 2 O O
Figure O O O O
1A. O O O O
Posteroanterior O O O O
radiographs O O O O
of O O O O
the O O O O
chest O O O O
taken O O O O
at O O O O
the O O O O
time O O O O
of O O O O
clinical O O O O
presentation O O O O
and O O O O
after O O O O
three O O O O
months O O O O
of O O O O
treatment. O O O O
Amiodarone O O O O
infiltrates O O O O
alveolointerstitial O O O O
bilateral O O O O
basal O O O O
lung O O O O
fields; O O O O
however, O O O O
media O O O O
have O O O O
at O O O O
follow-up O O O O
(image O O O O
further O O O O
below) O O O O
